Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06959459

Evaluation of the Safety and Efficacy of Artificial Bone Repair Materials for Repair of Long Bone Defects in the Extremities

Evaluation of the Safety and Efficacy of Artificial Bone Repair Materials for Repair of Long Bone Defects in the Extremities: A Prospective, Randomized Controlled, Single-Blind, Non-Inferiority Clinical Trial

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chinese PLA General Hosptial

Beijing, China

Location contact

Meng Li

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old and ≤ 60 years old, regardless of sex;
  • Cavitary bone defects in the limbs requiring bone grafting treatment;
  • Bone defect volume ≥ 1 cm³ and ≤ 8 cm³, with only one bone defect requiring intervention;
  • Subjects or their legal guardians can understand the study objectives, demonstrate sufficient compliance with the study protocol, and sign the informed consent form.

Exclusion criteria

  • Open fractures with wound contamination;
  • Repair of infectious bone defects;
  • Structural bone grafting required at the defect site;
  • Osteofascial compartment syndrome in the affected limb scheduled for surgery;
  • Presence of systemic infection, uncontrolled local infection at the surgical site, malignant tumor (including metastatic tumors) at the defect site, osteonecrosis at the defect site, severe nerve/soft tissue/vascular injury at the defect site, confirmed severe malnutrition, or dysfunction/failure of other vital organs;
  • Calcium and phosphorus metabolic abnormalities (calcium/phosphorus levels > 1.5 times the upper limit of normal values);
  • History of diabetes with fasting blood glucose ≥ 6.1 mmol/L;
  • Coagulation dysfunction (prothrombin time [PT] or activated partial thromboplastin time [APTT] > 2 times the upper limit of normal values);
  • Use of chemotherapeutic agents or receipt of radiotherapy within 3 months prior to enrollment;
  • Cumulative use of corticosteroids or growth factors for ≥ 14 days within 1 month prior to enrollment;
  • Long-term use of sedative-hypnotic drugs (continuous use for > 3 months) or non-steroidal anti-inflammatory drugs (NSAIDs, continuous use for > 3 months);
  • Known allergy to bovine-derived materials or collagen products;
  • Pregnant or lactating females;
  • Participation in other interventional clinical trials for drugs or medical devices within 1 month prior to enrollment;
  • Any other conditions where investigators, in their professional judgment, deem the subject ineligible to participate in the trial for the subject's safety or benefit.

Treatment and study plan

Intervention Group:Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.

Device

Use of artificial bone repair materials produced by Changzhou Bone-Renewal Medical Technologies LLC.

Control group: Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.

Device

Use of β-tricalcium phosphate bioceramics produced by Shanghai Biolu Biomaterials Co., Ltd.

Primary outcomes

  1. Bone graft fusion rate

    Time frame: 24weeks after surgery

Secondary outcomes

  1. Bone defect healing rate

    Time frame: 4 and 12 weeks after surgery

  2. New bone formation rate

    Time frame: 4, 12 and 24 weeks after surgery

  3. SF-36 scale

    Time frame: 24 weeks after surgery

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Chinese PLA General Hospital

Other

Registry information

Official study title

Evaluation of the Safety and Efficacy of Artificial Bone Repair Materials for Repair of Long Bone Defects in the Extremities: A Prospective, Randomized Controlled, Single-Blind, Non-Inferiority Clinical Trial

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 6, 2025
Registry last updated
May 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.